Therapies for the treatment of inflammatory bowel disease may have a potential use in patients with COVID-19.
Alimentary Pharmacology and Therapeutics reports on the final results from the GEMINI long-term safety study on vedolizumab, a gut-selective α4 β7 integrin antibody approved for moderately to severely active ulcerative colitis and Crohn disease.
An analysis of 3 large prospective cohorts examined the association between dietary patterns with high inflammatory potential and increased risks for Crohn disease and ulcerative colitis.
Researchers analyzed independent risk factors for short bowel syndrome in patients with Crohn disease in an effort to develop preventive strategies.
A team of investigators conducted a systematic review and meta-analysis to assess the risk of extraintestinal cancer in patients with inflammatory bowel disease.
Researchers compared the predictive properties of the IBDDI from among 5populations of individuals living with IBD, most of whom had Crohn disease as well.
Although cannabis use does not induce clinical remission in IBD, patient-reported quality of life may improve.
Positive resection margins, granulomas, and myenteric plexitis are all predictive of postoperative Crohn disease recurrence.
A longitudinal cohort study was conducted to validate the IBD-F scale in the assessment of clinically significant fatigue, as well as to identify the impact of fatigue on quality of life in patients with IBD.
This is the first study to report polymorphisms associated with long term response to anti-TNF treatment in pediatric patients with Crohn disease and ulcerative colitis.
Increased intestinal permeability may be associated with the development of Crohn disease.
The researchers note that surgery should typically be considered for patients who demonstrate an inadequate response to, develop complications from, or are nonadherent with medical therapy.
Ortikos, an anti-inflammatory corticosteroid, is approved as a once-daily treatment for mild to moderate active Crohn disease and for maintenance of clinical remission.
Study finds that patients with IBD and 1 or more comorbidities are at increased risk for viral or bacterial meningitis.
Significant improvements in both clinical symptoms (ie, abdominal pain, general well-being, nausea, diarrhea, and decreased appetite) as well as QoL scores were observed with cannabinoids.
A team of investigators assessed the accuracy of a machine learning model in grading the severity of ulcers in patients with Crohn disease.
Researchers evaluated the association of psoriasis and psoriatic arthritis with inflammatory bowel disease and other gastrointestinal illnesses.
Probiotics should only be recommended for specific patient populations since there is not enough evidence to support their use in the majority of digestive conditions, according to new clinical guidelines released by the American Gastroenterological Association (AGA) and recently published in Gastroenterology.
Steroid-sparing therapy may reduce risk for PFCs in young patients with Crohn disease
Variation in fecal calprotectin levels after ileocolonic resection is an accurate predictor of early endoscopic POR in patients with Crohn’s disease.